Clinical Report: AI-Assisted Antidepressant Selection by Physicians

Overview

This pilot investigation evaluates the integration of AI-driven Clinical Decision Support Systems (AI-CDSS) in antidepressant selection. The study finds that a Dynamic Clinician-Determined Weighting scheme enhances perceived clinical utility compared to other weighting methods.

Background

The management of Major Depressive Disorder (MDD) presents significant challenges due to the need for personalized treatment approaches that balance efficacy and side-effect risks. Current practices often rely on trial-and-error methods, leading to suboptimal outcomes for many patients. The integration of AI into clinical decision-making has the potential to provide data-driven insights while preserving clinician judgment.

Data Highlights

Key Findings

• The Dynamic Clinician-Determined Weighting scheme improved perceived clinical utility.
• 33.3% of physicians revised their initial antidepressant choices using the dynamic weighting approach.
• Both psychiatrists and primary care physicians used the adjustable weighting system.
• AI-CDSS can integrate clinician-defined weights for treatment outcomes.
• Effective AI integration requires balancing data-driven predictions with clinical agency.

Clinical Implications

The study presents the use of AI-CDSS with dynamic weighting capabilities to enhance treatment decision-making in MDD.

Conclusion

The study demonstrates AI-assisted decision support systems can improve antidepressant selection by allowing clinicians to adjust treatment criteria according to patient-specific factors.

Related Resources & Content

1. BMC Psychiatry, Springer, 2025 -- Comparative Analysis of Data-Driven and Conventional Approaches to Tailored Antidepressant Therapy: A Retrospective Study Utilizing Electronic Health Records
2. The ASCO Post, 2025 -- Novel AI Platform May Help Identify Patients Likely to Benefit Most From Clinical Trials
3. conexiant, 2025 -- Could This Tool Reduce Antidepressant Dropout?
4. asco ai in oncology — Clinical Staff Using Natural Language Processing Model Enhances Accuracy of Clinical Trial Prescreening Process
5. Overview | Depression in adults: treatment and management | Guidance | NICE
6. Nonpharmacologic and Pharmacologic Treatments of Adults in the Acute Phase of Major Depressive Disorder: A Living Clinical Guideline From the American College of Physicians
7. Management of Major Depressive Disorder (MDD) (2022) - VA/DOD Clinical Practice Guidelines
8. CAPLYTA (lumateperone) capsules, for oral use — Highlights of Prescribing Information
9. Efficacy and tolerability of antidepressants in individuals suffering from physical conditions and depressive disorders: network meta-analysis | The British Journal of Psychiatry | Cambridge Core
10. The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis - PubMed
11. A Decision-Support System to Personalize Antidepressant Treatment in Major Depressive Disorder
12. Artificial Intelligence in Depression – Medication Enhancement (AID-ME): A Cluster Randomized Trial of a Deep Learning Enabled Clinical Decision Support System for Personalized Depression Treatment Selection and Management | medRxiv
13. Personalising Antidepressant Treatment for Unipolar Depression Combining Individual Choices, Risks and big Data: The PETRUSHKA Tool: Personnalisation du traitement antidépresseur de la dépression unipolaire associant choix individuels, risques et mégadonnées: l’outil PETRUSHKA - PMC